True, but these are the ImmuneOncology (IO) drugs that are in the forefront and given the humongous therapeutic improvements they've brought and the associated billions of revenue that were generated and keep flowing, everyone and their mother have jumped on the IO bandwagon. Many more are in development and years ahead of Bex.
Also the combinations are being tried at pace that is nearly impossible to track. Keytruda being in the spotlight here as it will go off patent and Merck will go a mile (and some more) to keep the money flowing. Therefore numerous trials using combinations are launched, and since Merck has a need (and is sitting on a pile of cash since the Organon split-off) any biotech claims to be the ideal partner (and some can prove this with data from combo trials). Merck may choose more than one target to acquire in this space, but they are cautiously proceeding. BMS have some of their own up the sleeve, but who knows they may be looking for a novel target in IO. They were the originals with Yervoy.
Do not get me wrong, convinced long in Faron, for Bex and it;s tremendous potential. Sure that Merck is paying attention. As are many others cause the data is good. If a P2 headline corroborates this we're off.
yes, national phases on patents can take a while to be granted. One at a time they trickle in, and this one is a biggie as it pertains to the protection in the US for Bexy itself.
This patent describes the molecule and the way it binds to clever, for the predecessors and the final clinical candidate. Effectively this document safeguards Faron (and us) against other parties producing anti-clever antibodies based on the sequences in Bexy that interface with the target as well as antibodies that bind clever in a similar way and thus would be expected to elicit similar effect.
Since it was filed in 2017, it became public in 2018/19 (think it is a year and a half after filing date) so therefore the fact that it is granted by USPTO does not alter the fact that everyone including potential competitors could have devised their strategy regarding clever all along. as such it is not a reason to now disclose other knowledge as long as you think you can benefit from the lead.
Yeah, the anticipation is there. News can come some day.
The action indeed is on the Nas, where free trading of shares occurs in decent volumes. Where ones bid is registered in the bidbook, and when ask is below bid, orders are filled. Here an MM scoops up those shares shed by who no longer needs them and transfers those once or twice a day to the place where the action is.
great news, fantastic. Clevegen is the one that i bought the shares for. I started at 1.17 just after the large drop of traumakine, and added some on the ride down. When it became covid play i've been tempted to take the money and run, more than once. With captain hindsight at my side, i should have and bought back on the plunge of course, but glad i held. I have faith in this one, and will ride along for a while.